Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Semglee
| Field | Information |
|---|---|
| Medication Name | Semglee |
| Generic Name | Insulin glargine |
| Boxed/Label Warning | May cause serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening. Monitor blood glucose in all patients treated with insulin. |
| Purpose | Long-acting human insulin analog used to control high blood sugar in adults and children with diabetes mellitus. |
| Mechanism of Action | Semglee is a long-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. |
| Dosage Forms | Injectable solution (prefilled pen) |
| Available Strengths | 100 units/mL (U-100) |
| Dosage Frequency | Once daily, administered subcutaneously. |
| Common Side Effects | Injection site reactions (redness, swelling, itching), lipodystrophy (changes in fat tissue at the injection site), weight gain, hypoglycemia. |
| Serious Side Effects | Severe hypoglycemia, allergic reactions (rash, itching, swelling, difficulty breathing), hypokalemia (low potassium), anaphylaxis. |
| Drug Interactions | Other antidiabetic agents (e.g., sulfonylureas, GLP-1 receptor agonists), ACE inhibitors, ARBs, salicylates, alcohol, beta-blockers, corticosteroids, diuretics, thyroid hormones. |
| Important Notes | Rotate injection sites to prevent lipodystrophy. Monitor blood glucose regularly as directed by your healthcare provider. Do not share pens, even if the needle is changed. |
| Storage | Unopened pens should be stored in the refrigerator (36°F-46°F [2°C-8°C]). Once opened, pens can be stored at room temperature (below 86°F [30°C]) for up to 28 days. Do not freeze or expose to direct heat or light. |
| Missed Dose | Administer the dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and administer the next dose at your regularly scheduled time. Do not administer a double dose to make up for a missed dose. |
| Alternatives | Lantus, Basaglar, Tresiba, Levemir, Toujeo. |
Semglee Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Lantus (insulin glargine) | Long-acting insulin analog | The original brand-name insulin glargine product. |
| Basaglar (insulin glargine) | Long-acting insulin analog | Another biosimilar insulin glargine product. |
| Tresiba (insulin degludec) | Ultra-long-acting insulin analog | Provides a more stable and prolonged effect compared to insulin glargine. |
| Levemir (insulin detemir) | Long-acting insulin analog | May have a shorter duration of action compared to insulin glargine in some individuals. |
| Toujeo (insulin glargine) | Long-acting insulin analog (U-300 concentration) | More concentrated form of insulin glargine that may provide a longer duration of action in some individuals. |
Semglee Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Injection site reactions (redness, swelling, itching) | Severe hypoglycemia (low blood sugar) |
| Lipodystrophy (changes in fat tissue at the injection site) | Allergic reactions (rash, itching, swelling, difficulty breathing) |
| Weight gain | Hypokalemia (low potassium) |
| Hypoglycemia (low blood sugar) | Anaphylaxis |
Semglee Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Type 1 Diabetes | Individualized, typically 0.2 to 1.0 units/kg/day | Individualized, based on glycemic control | Administer subcutaneously once daily at the same time each day. Rotate injection sites. |
| Type 2 Diabetes | Individualized, typically 0.2 units/kg/day or 10 units daily | Individualized, based on glycemic control | Administer subcutaneously once daily at the same time each day. May be used in combination with oral antidiabetic medications. Rotate injection sites. |
Semglee Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $50 |
| Without Insurance (U.S.) | $200 |
| From CPS | $101 |
